Search research articles
Contact Us
Filters
Showing results (41-50 of 412) with videos related to
Page
of 42
Sort By:
Neurology
|
May 21, 2015
Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study
Daniel Weintraub, Kimberly Papay, Sharon X Xie
JAMA Neurology
|
July 12, 2016
The Danger of Not Treating Parkinson Disease Psychosis-Reply
Daniel Weintraub, Helen C Kales, Connie Marras
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 1, 2015
Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al
Inger van Steenoven, Dag Aarsland, Daniel Weintraub
JAMA Neurology
|
November 25, 2014
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability
Kara M Smith, Eli Eyal, Daniel Weintraub, et al.
The American Journal of Managed Care
|
April 18, 2008
Parkinson's disease--Part 2: Treatment of motor symptoms
Daniel Weintraub, Cynthia L Comella, Stacy Horn
The Lancet. Neurology
|
March 23, 2017
Cognitive decline before diagnosis of Parkinson's disease - Authors' reply
Anette Schrag, Daniel Weintraub, Jonathan M Schott
Nature Clinical Practice. Neurology
|
November 30, 2007
Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease
Marc N Potenza, Valerie Voon, Daniel Weintraub
The American Journal of Managed Care
|
April 18, 2008
Parkinson's disease--Part 3: Neuropsychiatric symptoms
Daniel Weintraub, Cynthia L Comella, Stacy Horn
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 5, 2007
Effect of age on geriatric depression scale performance in Parkinson's disease
Daniel Weintraub, Kirsten Saboe, Matthew B Stern
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 24, 2014
Psychiatric issues in cognitive impairment
Dag Aarsland, John-Paul Taylor, Daniel Weintraub
Page
of 42
Search research articles
Search
Showing results (41-50 of 412) with videos related to
Sort By:
Page
of 42
Neurology
|
May 21, 2015
Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study
Daniel Weintraub, Kimberly Papay, Sharon X Xie
JAMA Neurology
|
July 12, 2016
The Danger of Not Treating Parkinson Disease Psychosis-Reply
Daniel Weintraub, Helen C Kales, Connie Marras
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 1, 2015
Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al
Inger van Steenoven, Dag Aarsland, Daniel Weintraub
JAMA Neurology
|
November 25, 2014
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability
Kara M Smith, Eli Eyal, Daniel Weintraub, et al.
The American Journal of Managed Care
|
April 18, 2008
Parkinson's disease--Part 2: Treatment of motor symptoms
Daniel Weintraub, Cynthia L Comella, Stacy Horn
The Lancet. Neurology
|
March 23, 2017
Cognitive decline before diagnosis of Parkinson's disease - Authors' reply
Anette Schrag, Daniel Weintraub, Jonathan M Schott
Nature Clinical Practice. Neurology
|
November 30, 2007
Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease
Marc N Potenza, Valerie Voon, Daniel Weintraub
The American Journal of Managed Care
|
April 18, 2008
Parkinson's disease--Part 3: Neuropsychiatric symptoms
Daniel Weintraub, Cynthia L Comella, Stacy Horn
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 5, 2007
Effect of age on geriatric depression scale performance in Parkinson's disease
Daniel Weintraub, Kirsten Saboe, Matthew B Stern
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 24, 2014
Psychiatric issues in cognitive impairment
Dag Aarsland, John-Paul Taylor, Daniel Weintraub
Page
of 42